Dana-Farber Cancer Institute

Cancer specialty ranking: 3 (2025 US hospital rankings)

Dana-Farber Cancer Institute Founded in 1947, Dana-Farber Cancer Institute is the cancer specialty hospital affiliated with Harvard Medical School and a comprehensive cancer treatment center designated by the U.S. federal government. It has produced one Nobel Prize winner in Medicine.

Dana-Farber Cancer Institute's Specialties

  • In clinical aspects such as cancer gene positioning therapy, cancer immunotherapy, cancer endocrine therapy, cancer biotherapy, and cancer vaccines.

  • The hospital’s advantages in treating adult tumors are leading in the United States; and its treatment of pediatric tumors has been ranked first in the United States for many years.

Since its establishment, Dana-Farber Cancer Institute has been committed to providing professional and efficient medical services to cancer patients, while improving the understanding, diagnosis, treatment and prevention of cancer and related diseases through cutting-edge research. As an affiliated hospital of Harvard Medical School and a comprehensive cancer center designated by the U.S. federal government, Dana-Farber Cancer Institute also trains a new generation of doctors and experts, improves public medical care in high-risk areas and areas with low medical standards, and promotes advanced treatments and new scientific discoveries throughout the United States and around the world.

Currently, Dana-Farber Cancer Institute has 4,000 staff members and sees approximately 300,000 patients each year. There are more than 700 clinical trials available each year, and it is well-known worldwide for its dual advantages in clinical and research.

In 1996, Brigham and Women's Hospital joined with Dana-Farber Cancer Institute, a cancer treatment and research institution, to form the Dana-Farber/Brigham Cancer Center. Generally speaking, cancer patients receive outpatient treatment at Dana-Farber Cancer Institute, while inpatient treatment is at Brigham and Women's Hospital. The two institutions are connected by a sky bridge and combined into one, forming the Dana-Farber/Brigham Cancer Center. It has been rated as a leading and well-known cancer treatment center in the United States.

Dana-Farber/Brigham Cancer Center integrates a cancer research institute and a hospital, and has established 12 cancer specialties that integrate comprehensive medical care, surgery, radiotherapy and new clinical trials. It can treat lung cancer, breast cancer, gastric cancer, esophageal cancer, colorectal cancer, liver cancer, pancreatic cancer, leukemia, multiple myeloma, nervous system tumors, prostate cancer, kidney cancer, cervical cancer, osteosarcoma, head and neck cancer, skin cancer, melanoma, etc. Its milestone achievements include: developing the #1 and most accurate biomarker CA-125 test for ovarian cancer; pioneering new methods for evaluating and treating prostate cancer; developing advanced brain surgery tumor surgery techniques; pioneering selective internal radiation therapy for the liver, etc.

The current dean is Professor Edward J. Benz Jr., a professor at Harvard Medical School, a fund reviewer for the National Institutes of Health, and a world-renowned expert in the treatment of childhood cancer.

The hospital has many world-class tumor experts, including Joseph H. Antin, director of the stem cell transplantation program, who is also the chairman of the American Center for Blood and Marrow Transplantation. He is well-known in the industry for the treatment of stem cell transplantation, bone marrow transplantation, aplastic anemia, paroxysmal nocturnal hemoglobinuria, etc. Professor Judy Garber is the president of the American Association for Cancer Research and is dedicated to research on cancer genetics and prevention.

Hospital website: http://www.dana-farber.org

 

Dana-Farber Cancer Institute Basic Information